Filing summary
Entity and period: The supplied filing is Rexahn Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2018—not an Opus Genetics, Inc. filing. The filing describes Rexahn as a clinical-stage cancer drug developer.
Financial results and liquidity
- Revenue: None in the second quarter or first six months of 2018 or 2017. With no commercial sales, gross margin is not applicable.
- Second-quarter 2018: Operating expenses were $5.00 million, including $3.43 million of R&D and $1.57 million of G&A. Net loss was $3.84 million, or $0.12 per basic and diluted share, versus net income of $0.95 million in Q2 2017.
- First half 2018: Operating expenses were $10.89 million and net loss was $5.91 million, or $0.19 per share, compared with a $20.66 million net loss in the first half of 2017. The prior-year result included a $12.17 million noncash warrant fair-value loss; first-half 2018 included a $4.46 million noncash warrant fair-value gain.
- Cash flow: Operating cash use was $10.05 million in the first half, versus $8.27 million in the first half of 2017. Investing activities provided $6.25 million, mainly from securities redemptions; financing activities provided no cash. Cash and cash equivalents fell by $3.80 million to $5.09 million.
- Liquidity and balance sheet: Cash, cash equivalents and marketable securities totaled $16.74 million at June 30, 2018, down from $26.83 million at December 31, 2017. Current liabilities were $6.81 million; total liabilities included $3.39 million of warrant liabilities. The filing reports no conventional borrowings. Management said available cash and securities were expected to fund current activities for at least 12 months from issuance of the statements, while also stating additional capital would be needed to continue development.
- Other metrics: Total assets were $18.24 million and stockholders’ equity was $11.42 million. Accumulated deficit was $146.23 million. No income tax provision was recorded.
Changes and operating developments
- First-half R&D expense rose 55.8% to $7.49 million year over year, mainly due to higher drug-manufacturing costs ($2.09 million versus $0.63 million) and increased trial activity and enrollment for RX-3117 and RX-5902. G&A declined 1.0% to $3.40 million.
- RX-3117’s second stage of a Phase 2a pancreatic-cancer combination trial began in May 2018. Management reported earlier encouraging findings in pancreatic and advanced bladder cancer; the filing does not establish these as definitive efficacy results.
- For RX-5902 in metastatic triple-negative breast cancer, preliminary data announced in June indicated clinical response in five of the first ten evaluable patients and reported tolerability.
- In February 2018, Rexahn discontinued its internally funded RX-0201 metastatic renal-cell-cancer program and stopped enrolling patients, citing changes in the treatment landscape. The company also terminated its Asia collaboration arrangement relating to RX-0201; it recognized $368,750 of other income and agreed to pay Next BT royalties on potential Asian sales and a share of related licensing revenue, subject to a $5 million aggregate cap.
Outlook, risks and contingencies
- Management expected RX-3117 and RX-5902 costs to decrease in the remainder of 2018 as manufacturing campaigns were completed; RX-0201 costs were expected to remain flat while the renal-cell trial was wound down. These are expectations, not guarantees.
- The company warned that it has no product revenue, ongoing operating cash outflows, and will need additional capital. It said unavailable or unsatisfactory financing could force reductions in R&D. It could not estimate the cost or timing of completing development or when, if ever, product cash inflows might begin.
- Estimated remaining vendor costs for R&D services were approximately $7.48 million. A $1 million KRICT license milestone had not occurred. Future lease payments totaled approximately $351,935.
- A key financing risk was limited authorized-share capacity: shareholders rejected a proposed increase to 100 million shares in June, and a subsequent proposal sought an increase from 50 million to 75 million. As of August 3, the filing reported 7,634,027 shares available for other corporate purposes; failure to obtain approval could constrain equity financing and collaborations.
- Other material risks include clinical-trial and regulatory uncertainty, dependence on third-party research organizations and manufacturers, intellectual-property risks, and the volatility and estimation uncertainty of warrant fair values. Management reported disclosure controls were effective and no material change in internal control during the quarter.
Important facts to verify
- Confirm the filing is for Rexahn Pharmaceuticals, Inc.; the request identifies Opus Genetics, Inc., which does not match the document.
- Review the subsequent outcome of the proposed authorized-common-stock increase and Rexahn’s financing capacity.
- Check subsequent filings for actual cash burn, financing, and any change to the stated 12-month liquidity outlook.
- Verify later clinical-trial results for RX-3117 and RX-5902; the cited response observations were preliminary.
- Assess the noncash warrant valuation impact separately from operating performance and cash flow.